As the global health community continues to combat viral threats like SARS-CoV-2, identifying safe, fast-acting topical agents is a top priority. In 2020, a certified laboratory analysis in Mexico City confirmed that Ion Gel ZCM-25® achieves an unprecedented 99.9999% reduction of SARS-CoV-2 within just 10 minutes of direct contact.
This result, independently validated under cGMP conditions, positions Ion Gel ZCM-25® as a potential non-alcohol-based virucidal solution for clinical use, especially in high-risk settings where control of viral load is essential. In this article, we dive into the test protocol, the underlying IBAL technology, and the broader implications of these findings in infection control and viral resilience.
SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is highly transmissible and can remain viable on surfaces and in aerosols for extended periods. The virus enters host cells via ACE2 receptors, often concentrated in mucosal tissue, the respiratory tract, and skin microenvironments exposed to high human contact.
Because of this, healthcare professionals and patients alike require not just alcohol-based hand sanitizers but also topical agents that are non-drying, long-lasting, and safe for repeated use, especially on vulnerable or inflamed skin.
In 2020, a formal SARS-CoV-2 virucidal assay was conducted at the Laboratorio de Especialidades Inmunológicas (LEI) in Mexico City. The study followed EPA 2000 guidelines, a recognized international standard for antiviral product evaluation.
Key Study Information:
The exceptional activity of Ion Gel ZCM-25® against SARS-CoV-2 is due to its proprietary IBAL (Ion Biotechnology Aqueous Ligands) platform. This formulation includes biologically active ions:
These ions interact with viral envelopes and proteins, disrupting their ability to infect host cells. Unlike alcohol or bleach, this mechanism works without harsh solvents, making it suitable for repeated skin contact and mucosal applications.
This breakthrough result isn't an isolated case. Ion Gel ZCM-25® also demonstrated efficacy in parallel studies:
This breadth of performance confirms that ZCM-25® is not just an antiviral, but a multi-pathogen topical antimicrobial solution, ideal for clinical, emergency, and home use.
Based on virucidal testing, Ion Gel ZCM-25® has promising applications for SARS-CoV-2 prevention and management, including:
Its non-cytotoxic, non-irritating profile makes it compatible with skin that is already sensitized due to inflammation, eczema, or medical adhesives.
Most products rely on:
Ion Gel ZCM-25® works without alcohol, preserving the skin barrier and maintaining hydration. It also allows redox modulation, which has the added benefit of supporting mitochondrial repair and immune signaling, aligning with salutogenic healing principles.
Ion Gel ZCM-25® is backed by a full preclinical and clinical safety portfolio, which includes:
These results validate the product’s safe integration into long-term exposure protocols.
Recent studies suggest that SARS-CoV-2 modulates host redox states to enhance its replication. This makes redox-active agents like Ion Gel ZCM-25® strategically relevant.
By adjusting local oxidative stress through ionophoric delivery, the gel may contribute to:
| Feature | Ion Gel ZCM-25® Result |
|---|---|
| Contact Time | 10 minutes |
| SARS-CoV-2 Reduction | 99.9999% |
| Mechanism | Redox ionophore (Zn, Cu, Mg) |
| Safe for Skin & Mucosa | Yes |
| Additional Pathogen Efficacy | MRSA, Aspergillus, E. coli |
As emerging viral strains challenge public health systems, the development of non-antibiotic topical antivirals is critical. The validated SARS-CoV-2 results for Ion Gel ZCM-25® represent not just an endpoint, but a new beginning in topical infection control.
Its integration into clinical protocols, emergency preparedness, and public hygiene frameworks could improve response strategies to current and future viral outbreaks.
Full antiviral efficacy documentation:
https://zcm25.com/antiviral-activity-of-ion-gel-zcm-25-on-sars-cov-2-equine-viral-arteritis
Additional studies and clinical safety data:
https://zcm25.com/resources